GKWIM
CYCN icon

Gerber Kawasaki Wealth & Investment Management’s Cyclerion Therapeutics CYCN Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-102
Closed -$6K – 469
2021
Q3 		$6K Buy
+102
New +$6.68K ﹤0.01% 731

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's CYCN Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2021, closing a stake of 102 shares — an estimated $6K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in CYCN in Q3 2021 and held it in 1 quarter. The position peaked at $6K in Q3 2021. 56 funds tracked by Wall St. Rank hold CYCN as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Cyclerion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 102 Cyclerion Therapeutics shares in Q4 2021, an estimated $6K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Cyclerion Therapeutics in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Cyclerion Therapeutics position peaked at $6K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.